• Explore /
  • Poster
  • / A double-blind placebo-controlled randomized phase II trial assessing the activity and safety of regorafenib (REG) in patients (pts) with nonadipocytic soft tissue sarcoma (STS) previously treated with pazopanib (PAZ).

A double-blind placebo-controlled randomized phase II trial assessing the activity and safety of regorafenib (REG) in patients (pts) with nonadipocytic soft tissue sarcoma (STS) previously treated with pazopanib (PAZ).

Abstract Poster

Authors

null

Nicolas Penel

Oscar Lambret Cancer Center, Lille, France

Nicolas Penel , Jean-Yves Blay , Jennifer Wallet , Isabelle Laure Ray-Coquard , Axel Le Cesne , Thomas Ryckewaert , Antoine Italiano , Sebastien Salas , Corinne Delcambre , Emmanuelle Bompas , Francois Bertucci , Esma Saada-Bouzid , Loic Chaigneau , Christine Chevreau , Julien Thery , Emilie Decoupigny , Marie Vanseymortier , Marie-Cecile Le Deley , Olivier Mir

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2019 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Sarcoma

Track

Sarcoma

Sub Track

Soft Tissue Tumors

Clinical Trial Registration Number

NCT01900743

Citation

J Clin Oncol 37, 2019 (suppl; abstr 11021)

DOI

10.1200/JCO.2019.37.15_suppl.11021

Abstract #

11021

Poster Bd #

344

Abstract Disclosures

Similar Posters

First Author: Stephanie Clisant

First Author: Mark Andrew Dickson

First Author: Makoto Endo

First Author: Neal Shiv Chawla